Biotech Values

[DewDiligence]

What’s up with GSK’s branded-generics business?

http://in.reuters.com/article/2014/10/14/us-gsk-m-a-mature-drugs-idINKCN0I324T20141014

GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process.

Potential bidders include private equity firm KKR, India's Lupin and Denmark's Lundbeck, all of which are interested in acquiring rights to products in certain regions.

…The GSK brands up for sale include antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea. The company intends to retain the rights to such products in emerging markets, where they are still growing.